

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A method of reducing the risk of cataract development in a mammal comprising administering to the mammal an effective amount of a non-antimicrobial tetracycline derivative.

Claim 2 (cancelled).

Claim 3 (original): A method according to Claim 1, wherein said tetracycline derivative is a dedimethylaminotetracycline.

Claim 4 (original): A method according to Claim 3, wherein said dedimethylaminotetracycline is selected from the group consisting of 4-dedimethylaminotetracycline, 4-dedimethylamino-5-oxytetracycline, 4-dedimethylamino-7-chlorotetracycline, 4-hydroxy-4-dedimethylaminotetracycline, 5a,6-anhydro-4-hydroxy-4-dedimethylaminotetracycline, 6 α -deoxy-5-hydroxy-4-dedimethylaminotetracycline, 6-demethyl-6-deoxy-4-dedimethylaminotetracycline, 4-dedimethylamino-12a-deoxytetracycline, 12 α -deoxy-4-deoxy-4-dedimethylaminotetracycline, 12a, 4 α -anhydro-4-dedimethylaminotetracycline, 7-dimethylamino-6-demethyl-6-deoxy-4-dedimethylaminotetracycline, 5-hydroxy-6- α -deoxy-4-dedimethylaminotetracycline, 4-dedimethylamino-12 α -deoxyanhydrotetracycline and 4-dedimethylamino-11-hydroxy-12a-deoxytetracycline.

Claim 5 (original): A method according to Claim 1, wherein said tetracycline derivative is 6 α -deoxy 5-hydroxy 4-dedimethylamino tetracycline.

wherein: R7, R8, and R9 taken together in each case, have the following meanings:

R7	R8	R9
amino	hydrogen	hydrogen
nitro	hydrogen	hydrogen
azido	hydrogen	hydrogen
dimethylamino	hydrogen	azido
hydrogen	hydrogen	amino
hydrogen	hydrogen	azido
hydrogen	hydrogen	nitro
bromo	hydrogen	hydrogen
dimethylamino	hydrogen	amino
acylamino	hydrogen	hydrogen
hydrogen	hydrogen	acylamino
amino	hydrogen	nitro
hydrogen	hydrogen	(N,N-dimethyl)glycylamino
amino	hydrogen	amino
diethylamino	hydrogen	hydrogen
hydrogen	hydrogen	ethoxythiocarbonylthio
dimethylamino	hydrogen	methylamino
dimethylamino	hydrogen	acylamino
dimethylamino	chloro	amino
amino	chloro	amino
acylamino	chloro	acylamino
hydrogen	chloro	amino
amino	chloro	hydrogen
acylamino	chloro	hydrogen
mono alkyl amino	chloro	amino
nitro	chloro	amino

and pharmaceutically acceptable and unacceptable salts thereof.

Claims 18-34 (cancelled).

Claim 35: (currently amended): A method ~~according to Claim 7 of reducing the~~
risk of cataract development in a mammal comprising administering to the mammal a
~~wherein said antimicrobial tetracycline is administered~~ in an amount that is effective to
 reduce the risk of cataract development in a mammal but has substantially no antibacterial
 activity.

Claim 36 (cancelled).

Claim 37 (new): A method according to Claim 35, wherein said tetracycline is administered systemically.

Claim 38 (new): A method according to Claim 37, wherein said tetracycline is administered systemically by a controlled release delivery system.

Claim 39 (new): A method according to Claim 35, wherein said tetracycline is administered orally.

Claim 40 (new): A method according to Claim 35, wherein said tetracycline is administered topically.

Claim 41 (new): A method of reducing the risk of cataract development in a mammal comprising administering to the mammal an effective amount of minocycline.

Claim 42 (new): A method according to Claim 41, wherein said minocycline is administered systemically.

Claim 43 (new): A method according to Claim 42, wherein said minocycline is administered systemically by a controlled release delivery system.

Claim 44 (new): A method according to Claim 41, wherein said minocycline is administered orally.

Claim 45 (new): A method according to Claim 41, wherein said minocycline is administered topically.

Claim 46: (new): A method according to Claim 41 wherein said minocycline is administered in an amount that is effective to reduce the risk of cataract development in a mammal but has substantially no antibacterial activity.

Claim 47 (new): A method of reducing the risk of cataract development in a mammal comprising administering to the mammal an effective amount of doxycycline.

Claim 48 (new): A method according to Claim 47, wherein said doxycycline is administered systemically.

Claim 49 (new): A method according to Claim 48, wherein said doxycycline is administered systemically by a controlled release delivery system.

Claim 50 (new): A method according to Claim 47, wherein said doxycycline is administered orally.

Claim 51 (new): A method according to Claim 47, wherein said doxycycline is administered topically.

Claim 52: (new): A method according to Claim 47 wherein said doxycycline is administered in an amount that is effective to reduce the risk of cataract development in a mammal but has substantially no antibacterial activity.

Claim 53 (new): A method of reducing the risk of cataract development in a mammal comprising administering to the mammal an effective amount of tetracycline wherein said tetracycline is administered systemically or orally.